All In Biotech

Drug Trial Radar · NCT04817956

Improving Public Cancer Care by Implementing Precision Medicine in Norway

Improving Public Cancer Care by Implementing Precision Medicine in Norway A Multi-cohort Phase 2 Treatment Clinical Study Investigating Efficacy of Approved Drugs Outside Indication in Patients With Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Apr 1, 2021

Primary completion

Mar 30, 2040

Study completion Apr 30, 2045

Sponsor

Lead sponsor
Oslo University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Haukeland University Hospital; St. Olavs Hospital; University Hospital of North Norway; University Hospital, Akershus; Vestre Viken Hospital Trust; Hospital of Southern Norway Trust; Ostfold Hospital Trust; The Hospital of Vestfold; Helse Stavanger HF; Nordlandssykehuset HF; Sykehuset Innlandet HF; Helse Forde; Helse Fonna; Helse Nord-Trøndelag HF; Helse Møre og Romsdal HF; Sykehuset Telemark; Lovisenberg Diakonale Hospital
First posted
Mar 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.

Conditions

  • Cancer Metastatic

Interventions

  • AtezolizumabDrug

    drugs used outside indication, based on biomarker

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 16 weeks clinical responseTime frame: 16 weeks
  2. Access to drugs for patientsTime frame: 4 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Sykehuset Ålesund

    Ålesund, Norway · Not yet recruiting

  • Haukeland universitetssykehus

    Bergen, Norway · Recruiting

  • Nordlandssykehuset

    Bodø, Norway · Recruiting

  • Vestre Viken Hospital

    Drammen, Norway · Recruiting

  • Førde Hospital

    Førde, Norway · Recruiting

  • Sykehuset Innlandet

    Hamar, Norway · Recruiting

  • Helse Fonna

    Haugesund, Norway · Not yet recruiting

  • Sørlandet sykehus

    Kristiansand, Norway · Recruiting

  • Sykehuset Levanger

    Levanger, Norway · Not yet recruiting

  • Oslo University Hospital

    Oslo, Norway · Recruiting

  • Ahus

    Oslo, Norway · Recruiting

  • Sykehuset Telemark

    Skien, Norway · Recruiting

  • Stavanger universitetssykehus

    Stavanger, Norway · Recruiting

  • Sykehuset Vestfold

    Tønsberg, Norway · Not yet recruiting

  • Universitetssykehuset i Nord-Norge

    Tromsø, Norway · Recruiting

  • St Olavs Hospital

    Trondheim, Norway · Recruiting

  • Sykehuset Østfold Kalnes

    Fredrikstad, Østfold fylke, Norway · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.